Somatic comorbidities and Alzheimer's disease treatment. - Wikidata - wikimedia - TriplyDB

Somatic comorbidities and Alzheimer's disease treatment.

Somatic comorbidities and Alzheimer's disease treatment.

http://www.wikidata.org/entity/Q37199794

about

Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data.Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease.The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.

P2860

Q31160667-64E47E7E-5745-4E5E-967A-BE6B7C4565F7 Q35169922-7E910CF3-5B6F-45A6-9248-EEB0499FB83F Q53385171-2C8709F2-63CE-440D-A7BB-37396BE469E5

P2860

Somatic comorbidities and Alzheimer's disease treatment.

http://www.wikidata.org/entity/Q37199794

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Somatic comorbidities and Alzheimer's disease treatment.

@en

Somatic comorbidities and Alzheimer's disease treatment.

@nl

type

label

Somatic comorbidities and Alzheimer's disease treatment.

@en

Somatic comorbidities and Alzheimer's disease treatment.

@nl

prefLabel

Somatic comorbidities and Alzheimer's disease treatment.

@en

Somatic comorbidities and Alzheimer's disease treatment.

@nl

P1433

Q37199794-719243BE-BFD2-4BF3-9440-F7D7A7551568

P1476

Q37199794-2E2A11B8-1595-4EA4-997C-5CE6E0B906C4

P2093

Q37199794-0099261D-7A5E-49C4-B08B-E6BC89FB4CD6

Q37199794-16997958-898D-43D1-93C2-C4822E722A41

Q37199794-3B86754E-31EF-4DFB-84AD-C1F8136929A6

Q37199794-7E1E0DCD-126D-4115-B034-0F873D9FC412

Q37199794-9839AC8A-3049-4A48-9F7C-83B242A4BDB6

Q37199794-B51C6243-0C8D-4F7D-9D79-00386CAF1814

Q37199794-C3F5D257-0F4F-48BC-8F2D-8B2DD4C6E131

Q37199794-E68C1F58-C82C-436C-AEE4-BA60CEFF3708

P2860

Q37199794-060AA360-D3EA-46BF-9966-0B610133325F

Q37199794-0C57A724-E167-4E6E-9A08-29ED8ADE9B5C

Q37199794-0DAEE198-1444-4CE5-821D-14A05608AA09

Q37199794-12CDAD25-8C33-46F3-8112-964167645F43

Q37199794-17E2E466-7437-4867-B0CD-54EDF56209EA

Q37199794-18D2D7C0-3AED-4A34-BC99-5F43F5FE4531

Q37199794-19A05E91-5199-4180-A905-C5A5EB872CF9

Q37199794-2204675C-4F16-474E-B338-314791574F31

Q37199794-23213923-CA00-47B6-9313-BC7496E83442

Q37199794-239FC106-8AA4-45F1-A599-6CF8543C4400

P2888

Q37199794-F7103C4D-5379-428C-9E84-272B7DBE8213

P304

Q37199794-969D665A-4325-4DD3-906F-295900BDBF19

P31

Q37199794-43023543-D782-4125-A0EF-9A458E2A78FF

P356

Q37199794-2A2BB30F-F446-420B-975E-4C1D2376C39F

P433

Q37199794-90BC331F-FAAF-4868-8B40-CD138AA12BC7

P478

Q37199794-AE66FFD9-F1C4-49BC-9D22-D72DAA998DCF

P50

Q37199794-7D8044E1-CC6C-4D58-95CE-7C46AE09FAA9

P577

Q37199794-BE08EED1-5F3E-4DAC-B011-271FFC21271D

P5875

Q37199794-083A3765-8E54-484E-819D-A5B8F4D6283F

P698

Q37199794-C12E12E4-03E2-4DCB-A381-164EE33C5F6E

P921

Q37199794-8C392ABF-747A-4045-B49E-A5E571FCCB80

P932

Q37199794-4BE24C6B-5CFB-4893-BF2B-81B664BFA6D8

P356

S10072-013-1290-3

P1433

Neurological Sciences

P1476

Somatic comorbidities and Alzheimer's disease treatment

@en

P2093

Alberto Castagna

http://www.w3.org/2001/XMLSchema#string

Alessandra Clodomiro

http://www.w3.org/2001/XMLSchema#string

Amalia Cecilia Bruni

http://www.w3.org/2001/XMLSchema#string

Francesca Frangipane

http://www.w3.org/2001/XMLSchema#string

Gianfranco Puccio

http://www.w3.org/2001/XMLSchema#string

Pietro Gareri

http://www.w3.org/2001/XMLSchema#string

Roberto Lacava

http://www.w3.org/2001/XMLSchema#string

Valeria Graziella Laura Manfredi

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of Dementia, Alzheimer's Disease, and Vascular Dementia in Italy. The ILSA Study

Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults

Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons.

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.

Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

Alzheimer's disease: clinical trials and drug development.

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway.

Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.

P2888

s10072-013-1290-3

P304

1581-1589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10072-013-1290-3

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257474997

http://www.w3.org/2001/XMLSchema#string

P698

23370896

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3784058

http://www.w3.org/2001/XMLSchema#string